BioCentury | Mar 17, 2021
Management Tracks

High-profile departures at Sage, bluebird as Cloonan, Davidson depart; plus CBC Group, Turning Point, Agilent, Intercept, Centessa, Beam and more

...will be acting interim principal financial officer. Baker previously served as VP of finance at Cleave Biosciences...
BioCentury | Dec 24, 2019
Company News

Rival suitor could have pressed Synthorx takeout price even higher than winning $2.5B Sanofi bid

...and CEO is Laura Shawver, who joined in November 2017 after serving as CEO of Cleave Biosciences Inc....
BioCentury | Dec 9, 2019
Company News

Sanofi broadens oncology capabilities, adds IL-2 program via $2.5B Synthorx takeout

...and CEO is Laura Shawver, who joined in November 2017 after serving as CEO of Cleave Biosciences Inc....
BioCentury | Aug 7, 2019
Financial News

VCs recapitalize Cleave around next-gen molecule

...second-generation cancer compound following a toxicity snag for the company's first-generation version. Formerly known as Cleave Biosciences Inc....
BioCentury | Mar 15, 2019
Tools & Techniques

Synthetic solutions for immuno-oncology

...short half-lives. Shawver joined Synthorx in late 2017; she previously was CEO and director of Cleave Biosciences Inc....
...and Institutions Mentioned Ambrx Inc., La Jolla, Calif. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Cleave Biosciences Inc....
BioCentury | Nov 28, 2017
Company News

Management Tracks: Synthorx, Vir

...Jolla, Calif.) hired Laura Shawver as president, CEO and a director. She was CEO of Cleave Biosciences Inc....
BioCentury | Aug 22, 2017
Company News

Management tracks: Akari, Turnstone, Iconic

...company Atara Biotherapeutics Inc. (NASDAQ:ATRA) appointed Kanya Rajangam CMO and SVP. She was CMO at Cleave Biosciences Inc....
BioCentury | Feb 28, 2017
Clinical News

Caltech group finds proteasome inhibitor with novel MOA

...California Institute of Technology , was founder of Proteolix Inc. , which created carfilzomib, and Cleave Biosciences Inc....
BioCentury | Jan 7, 2017
Company News

Management tracks

...who left the company. Young was CFO and treasurer at OvaScience Inc. (NASDAQ:OVAS). Oncology company Cleave Biosciences Inc....
BioCentury | Aug 15, 2016
Finance

De-risking first in class

Cleave Biosciences Inc. has steered clear of non-dilutive partnership dollars in hopes of internally validating the profile of its first-in-class cancer therapeutic CB-5083 . Now, the biotech has attracted a cadre of new investors in last...
Items per page:
1 - 10 of 33
BioCentury | Mar 17, 2021
Management Tracks

High-profile departures at Sage, bluebird as Cloonan, Davidson depart; plus CBC Group, Turning Point, Agilent, Intercept, Centessa, Beam and more

...will be acting interim principal financial officer. Baker previously served as VP of finance at Cleave Biosciences...
BioCentury | Dec 24, 2019
Company News

Rival suitor could have pressed Synthorx takeout price even higher than winning $2.5B Sanofi bid

...and CEO is Laura Shawver, who joined in November 2017 after serving as CEO of Cleave Biosciences Inc....
BioCentury | Dec 9, 2019
Company News

Sanofi broadens oncology capabilities, adds IL-2 program via $2.5B Synthorx takeout

...and CEO is Laura Shawver, who joined in November 2017 after serving as CEO of Cleave Biosciences Inc....
BioCentury | Aug 7, 2019
Financial News

VCs recapitalize Cleave around next-gen molecule

...second-generation cancer compound following a toxicity snag for the company's first-generation version. Formerly known as Cleave Biosciences Inc....
BioCentury | Mar 15, 2019
Tools & Techniques

Synthetic solutions for immuno-oncology

...short half-lives. Shawver joined Synthorx in late 2017; she previously was CEO and director of Cleave Biosciences Inc....
...and Institutions Mentioned Ambrx Inc., La Jolla, Calif. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Cleave Biosciences Inc....
BioCentury | Nov 28, 2017
Company News

Management Tracks: Synthorx, Vir

...Jolla, Calif.) hired Laura Shawver as president, CEO and a director. She was CEO of Cleave Biosciences Inc....
BioCentury | Aug 22, 2017
Company News

Management tracks: Akari, Turnstone, Iconic

...company Atara Biotherapeutics Inc. (NASDAQ:ATRA) appointed Kanya Rajangam CMO and SVP. She was CMO at Cleave Biosciences Inc....
BioCentury | Feb 28, 2017
Clinical News

Caltech group finds proteasome inhibitor with novel MOA

...California Institute of Technology , was founder of Proteolix Inc. , which created carfilzomib, and Cleave Biosciences Inc....
BioCentury | Jan 7, 2017
Company News

Management tracks

...who left the company. Young was CFO and treasurer at OvaScience Inc. (NASDAQ:OVAS). Oncology company Cleave Biosciences Inc....
BioCentury | Aug 15, 2016
Finance

De-risking first in class

Cleave Biosciences Inc. has steered clear of non-dilutive partnership dollars in hopes of internally validating the profile of its first-in-class cancer therapeutic CB-5083 . Now, the biotech has attracted a cadre of new investors in last...
Items per page:
1 - 10 of 33